Li Guangchen
The A-share listed company Jiu’an Medical can be described as “money” with unlimited prospects. In the first three quarters of this year alone, the company’s net profit attributable to the parent company increased by nearly 320 times year-on-year. Under the domestic epidemic this year, the benefits of nucleic acid testing can be seen. Joan Medical took the opportunity to go overseas, and the US subsidiary signed an iHealth kit procurement contract with the US DLA (U.S. Department of Defense Logistics Agency) in November. Joan Medical and the time race finally seized the opportunity again.
Jiu’an Medical, Tianjin Jiu’an Medical Electronics Co., Ltd., was established on August 22, 1995. Its main business is the research and development, production and sales of household medical devices. In the current entire market, the impact of the epidemic still exists. In addition to domestic demand, nucleic acid detection kits can be exported to the United States and other markets, giving Joan Medical more opportunities. However, as a medical device company, the “laying down” of the test box in front of it can only be temporary. It may be the long-term solution to use the money earned from nucleic acid testing to invest in product research and development to produce competitive medical devices.
Beer
Is it useful for us Chinese people?
This article is reproduced from: https://www.fortunechina.com/jingxuan/25206.htm
This site is only for collection, and the copyright belongs to the original author.